Moreover, the affinity of those benzimidazole-based FLT3 inhibitors to cause severe myelosuppression as an urgent side effect resulting from the inhibition of c-kit kinase; should be tested to depict the efficacy of those FLT3 inhibitors to target FLT3 AML cells with fewer and less urgent side effects. This evidence concerns the gene FLT3 and acute myeloid leukemia.